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Abstract 
 
It has previously been reported that leptin may be involved in nicotine’s ability to reduce body 
weight. Our aim was to investigate whether the anorexic action of nicotine is related to the actions 
of leptin by utilizing lean leptin-sensitive and obese leptin-resistant Psammomys obesus (P.obesus). 
Lean and obese P. obesus were assigned to receive nicotine sulphate at 6, 9 or 12mg day-1 or saline 
(control) for nine days (n = 6-10 in each group) administered using mini-osmotic pumps. Food 
intake, body weight, plasma leptin concentrations, plasma insulin and blood glucose were 
measured at baseline and throughout the study period. Nicotine treatment reduced food intake by 
up to 40% in lean and obese P. obesus. Plasma leptin levels fell significantly only in lean nicotine 
treated animals, whereas no changes were observed in obese nicotine treated animals. However, 
both lean and obese nicotine treated animals had similar reductions in body weight. Our results 
show that nicotine has dramatic effects on food intake and body weight, however these changes 
appear to be independent of the leptin signaling mechanisms.  
 
 
Introduction 
 
Numerous studies have demonstrated an inverse relationship between tobacco smoking and body 
weight (1-6). This action of smoking appears to be nicotine mediated as indicated by Hajek et al. 
(7) who demonstrated significantly lower weight gain in individuals using nicotine chewing gum 
for 12 months compared to alternative non-nicotine treatments.  
 
Although not fully understood, several mechanisms have been proposed to account for the 
actions of nicotine in lowering body weight. Nicotine binding sites have been demonstrated in 
appetite-regulating regions of the hypothalamus (8) suggesting that centrally mediated actions 
contribute to increased energy expenditure during nicotine treatment (9). Recently Yoshida et al. 
(6) demonstrated that nicotine treatment also appeared to act peripherally by increasing mRNA 
and protein content of uncoupling protein 1 in both brown and white adipose tissue. 
 
These actions of nicotine on both hypothalamic appetite centres and peripheral metabolism 
suggest a possible link between nicotine and the anorexic hormone, leptin. Leptin is known to be 
an important regulator of appetite, peripheral energy expenditure and fuel homeostasis (10, 11). 
Leptin is primarily secreted by adipocytes in proportion to adipose tissue mass, such that leptin 
levels are higher in obese compared to lean subjects, indicating leptin resistance (12). An 
epidemiological study demonstrated a link between the actions of nicotine on body weight and 
leptin, suggesting that smoking via nicotinic mechanisms may modify the sensitivity of leptin 
receptors (13). 
 
P. obesus are desert rodents which when fed a standard laboratory diet a proportion of the 
animals remain lean while others develop varying degrees of obesity and diabetes (14) similar to 
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that observed in susceptible human populations (15). We have previously demonstrated that in P. 
obesus exogenous leptin infusion reduced bodyweight in lean animals (16), whereas obese 
animals were unaffected by leptin infusion suggesting a disruption in the leptin signaling 
pathway. We propose that if the actions of nicotine on weight loss are inter-connected with leptin 
signaling, diminished sensitivity to nicotine might be expected in obese P. obesus. To examine 
this relationship plasma leptin levels were measured in both lean leptin-sensitive and obese 
leptin-resistant P. obesus during mini-osmotic pump nicotine delivery.   
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Methods and Materials 
Animals. 
 
Mixed sex P. obesus were maintained on a 12 hr light-dark cycle at 21±1oC and fed ad libitum 
standard rat chow (Barastoc, Pakenham, Australia). One week prior to the study commencement, 
baseline measurements were taken including food intake, body weight, blood glucose, plasma 
insulin and plasma leptin concentrations (n=66). Using these baseline parameters 16 week old P. 
obesus were selected and divided into two groups, lean (n=37) and obese/insulin resistant (n=29). 
Within each group, animals were randomly subdivided to receive nicotine sulphate at 6, 9 or 
12mg day-1 or saline (sham controls) for nine days via mini-osmotic pumps (Alzet model 2002, 
CA) implanted subcutaneously between the scapulae under light anesthetizia (sodium 
pentobarbitol, 60mg/kg). Animals were allowed to recover for 48 hours before daily bodyweight 
and food intake measurements were monitored. During the study period blood was taken for 
glucose, insulin and leptin measurements. All experimental procedures were performed 
according to institutional (Deakin University Animal Ethics Committee) guidelines. 
 
Biochemical Analyses. 
 
Blood was collected from the tail vein in heparinized microtubes and blood glucose determined 
using an automated enzymatic analyzer (2300 Stat Plus, Yellow Springs Instruments, Ohio). 
Plasma leptin levels were measured by radioimmunoassay using a multi-species primary 
antibody (Linco, St Charles, MO). Plasma insulin levels were determined by radioimmunoassay 
using a human primary antibody (Phadeseph, Kabi Pharmacia Diagnostics, Sweden).  
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Statistical analysis 
 
All results are expressed as means ± SEM. Paired sample t test were used to evaluate differences 
between the start and end of the study while unpaired t-tests were used for comparisons between 
lean and obese animals within each respective group. One-way analysis of variance (ANOVA) 
followed by LSD post-hoc analysis was performed. In all instances, p<0.05 was considered 
significant. Analyses were performed using SPSS statistical software (version 10.0 for Windows, 
Chicago, IL). 
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Results  
 
Effects of nicotine on Body Weight, Food Intake and Metabolic Characteristics 
 
In comparison to lean P. obesus, obese animals had increased plasma insulin and leptin levels at 
the beginning of the study (Table 1). After 9 days of nicotine infusion, the lean 6mg day-1 group 
showed a no change in food intake from baseline levels, whereas food intake was significantly 
reduced in the lean 9 and 12mg day-1 groups by 26 and 46% respectively (Table 1), 
demonstrating a dose dependent reduction in food intake with increasing nicotine dose. Nicotine 
treated obese animals showed relatively consistent reductions in food intake ranging between 30 
and 38% (Table 1). No significant differences in food intake were observed in saline treated lean 
or obese controls (Table 1). Bodyweight was significantly reduced for all lean and obese nicotine 
treated groups (Table 1, Fig 1A) ranging from 5 to 10%. Control lean and obese P. obesus 
showed no significant changes in body weight during the study period (Table 1, Fig 1A).   
 
Plasma leptin concentrations were significantly reduced by up to 50% in the lean 9 and 12mg 
day-1 nicotine treated P. obesus, whereas no effect of nicotine treatment was evident in obese 
animals (Table 1, Fig 1B). Plasma insulin levels decreased in most nicotine treated groups, being 
most marked in the obese hyperinsulinemic animals where 3-fold reductions were observed. 
Blood glucose levels remained unchanged throughout the study period (Table 1). 
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Discussion 
This study demonstrated that continuous nicotine infusion significantly lowered body weight and 
food intake in both lean and obese P. obesus. These changes occurred in the presence of 
significantly reduced plasma leptin concentrations in lean P. obesus, whereas in obese animals 
leptin levels remained unchanged. Previously we have demonstrated that high levels of 
exogenous leptin were successful only in reducing food intake and body weight in lean leptin 
sensitive animals without affect in obese animals, indicating severe leptin resistance (17). Hodge 
et al (13) demonstrated a link between the actions of nicotine on body weight and leptin, 
suggesting that smoking via nicotinic mechanisms may modify the sensitivity of leptin receptors. 
If the actions of nicotine on food intake and weight loss are inter-connected with leptin signaling, 
we would expect obese leptin-resistant animals to have no or a diminished response to nicotine in 
relation to reducing food intake and body weight compared to lean leptin-sensitive animals. 
Therefore, the effectiveness of nicotine to lower body weight in both lean and leptin-resistant 
obese P. obesus demonstrates that functional leptin signaling is not required for the suppression 
of body weight by nicotine.  
 
The reductions in food intake and body weight seen in P. obesus in response to continuous 
nicotine infusion are consistent with previous literature in rodents (1-6). However, P. obesus 
required close to double the infusion dose to achieve a comparable degree of weight loss. 
Preliminary investigation using lower doses of nicotine (5mg·kg-1·day-1) failed to suppress body 
weight. Interestingly in lean P. obesus receiving the lowest nicotine dose (6mg day-1), food intake 
remained constant although body weight decreased. This may suggest an increase in metabolic 
rate without a lowered food intake or a possible transient reduction in food intake as observed 
previously with low-dose nicotine treatment (4).  
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 Obese P. obesus, consistent with our previous studies (17) had circulating leptin concentrations 
which were significantly higher than lean animals. Following nicotine treatment, the loss of body 
weight and reduction in food intake was not accompanied by any alteration in circulating leptin 
levels in these obese animals. In contrast, lean P. obesus treated with 9 and 12mg day-1 nicotine 
doses demonstrated significantly lowered plasma leptin concentrations. From our study it is 
unclear why decreases in body weight were accompanied by reductions in leptin in lean animals 
only. It is possible that this is the result of significant falls in insulin in the lean animals, as 
insulin is known to stimulate the release of leptin (18). In obese animals, although insulin levels 
were also significantly reduced, these animals remained obese and insulin resistant thereby 
possibly maintaining higher leptin concentrations. Further, it would have be interesting to 
examine alterations in body fatness with nicotine treatment in both lean and obese animals and 
determine if there was any dysregulation in leptin production from various fat depots. 
 
As there is no evidence of a relationship between leptin and the anorexic actions of nicotine 
found in this study, the results suggest that the inhibitory effect of nicotine on food intake and 
body weight are most likely mediated via an alternative neural pathway. Nicotine is known to 
inhibite neuropeptide Y (NPY) (a potent stimulator of food intake) synthesis and increase 
dopamine and serotonin levels in the cortex (19) and lateral hypothalamus(4). Further, nicotine 
has also been shown to act in the paraventricular nucleus by indirectly activating corticotropin-
releasing hormone, which is an inhibitor of food intake (20). Together, these neuropeptides most 
likely contribute to the anorexic effect of nicotine however further studies are required to 
elucidate the mechanism of nicotine’s effect on energy balance.  
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In summary, nicotine has dramatic effects on food intake and body weight in both lean leptin-
sensitive and obese leptin-resistant P.obesus. Significant changes in plasma leptin concentrations 
occurred in lean nicotine treated animals only. These changes appear to be secondary to 
nicotine’s affect on food intake as both lean leptin-sensitive and obese leptin-resistant P. obesus 
had similar reductions in body weight. We can hypothesize that nicotine’s effects on food intake 
are mediated through the central nervous system by affecting a number of neurotransmitters 
involved in energy homeostasis and indirectly activating the sympathetic nervous system, 
although these actions appear to be independent of the leptin signaling pathway. 
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Legend to Figure 
 
Figure 1: Percent change in body weight (A) and plasma leptin (B) from baseline measurements 
after 9 days of continuous nicotine infusion at 6, 9 and 12mg day-1. Lean P. obesus indicated in 
open bars, obese P. obesus in solid bars. Values are means ± SEM. Significantly different from 1 
week run-in period, * p<0.05, # p<0.01. 
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Table 1 
 Study Control Nicotine (mg day-1) 
 Period  6 9 12 
Food intake (g/day)  (n=9) (n=9) (n=10) (n=9) 
Lean Start 12.5 ± 0.7 12.1 ± 0.8 14.7 ± 1.1 11.6 ± 0.8 
 End 13.9 ± 0.6 12.6 ± 1.3     9.9 ± 2.0b     6.9 ± 2.1b 
      
  (n=8) (n=6) (n=7) (n=8) 
Obese Start 13.3 ± 0.8 13.6 ± 0.9 13.9 ± 1.1 15.1 ± 1.4 
 End 13.5 ± 0.7 9.0 ± 1.7    8.2 ± 1.7b     9.8 ± 1.5b 
Body weight (g)      
Lean Start 170 ± 11 168 ± 11 182 ± 11 181 ± 8 
 End 172 ± 10 159 ± 12b     162 ± 9b   169 ± 9b 
      
Obese Start 203 ± 9a   195 ± 13a  212 ± 13a  212 ± 7a 
 End  206 ± 7   179 ± 12b     192 ± 9b    202 ± 10b 
Leptin (ng/ml H.E.)      
Lean Start 51 ± 9 32 ± 7 56 ± 8 58 ± 9 
 End 46 ± 10 20 ± 5  30 ± 7b  31 ± 6b 
      
Obese Start  78 ± 5a 78 ± 8a  84 ± 3a    75 ± 10a 
 End 70 ± 7 68 ± 11 76 ± 6 77 ± 7 
Insulin (μU/ml)      
Lean Start 71 ± 12 43 ± 6 106 ± 23   72 ± 13 
 End 53 ± 11   46 ± 11     42 ± 12b   25 ± 4b 
      
Obese Start  301 ± 59a    454 ± 127a  422 ± 70a  502 ± 95a 
 End 214 ± 46  101 ± 38b  102 ± 19b  167 ± 67b 
Glucose (mmol/L)      
Lean Start   3.7 ± 0.2   4.2 ± 0.2   4.2 ± 0.1   4.1 ± 0.2 
 End   4.2 ± 0.2   4.2 ± 0.2   4.6 ± 0.2   5.1 ± 0.5 
      
Obese Start   4.6 ± 0.3   4.5 ± 0.3   5.5 ± 0.5   5.0 ± 0.5 
 End   4.7 ± 0.4   4.3 ± 0.4   4.4 ± 0.4   4.4 ± 0.3 
a  Significantly different (p<0.05) from respective lean group at the start of study, 
b  Significantly different (p<0.05) from start of study. 
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 Figure 1 
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